Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
The Role of GLP-1 in Heart Failure
Author(s): Amina Rakisheva , Anton Zatsarinnyy Added: 6 days ago

Heart Failure

Inherited and Congenital Cardiac Conditions
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 3 months ago

Heart Failure
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 6 months ago

Cardiovascular Renal Metabolic
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Cardiovascular Renal Metabolic

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 9 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
EASD 24: Effectiveness of Empagliflozin and GLP1s
Author(s): Phyo Htoo Added: 1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Targeting Obesity for Heart Failure
Author(s): Emily Morris , Oliver J Rider Added: 1 month ago

Cardiovascular Renal Metabolic

Heart Failure
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 6 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Renal Metabolic

Heart Failure
Finerenone: Will It Be a Game-changer?
Author(s): Dinesh Khullar , Anish Kumar Gupta , Kulwant Singh Added: 1 year ago

Cardiovascular Renal Metabolic

Heart Failure